Trial Profile
A longitudinal study of Florbetapir F 18 in patients participated in the Alzheimer'sDiseaseNeuroimaging Initiative (ADNI)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Sep 2015
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 08 Sep 2015 New trial record
- 17 Aug 2015 Results published in the JAMA Neurology.